Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 6, 2015, Pages 1021-1030

  Sprague, Stuart M ^a   Wetmore, James B ^b   Gurevich, Konstantin ^c   Roza, Gerald Da ^d   Buerkert, John ^e   Reiner, Maureen ^f   Goodman, William ^f   Cooper, Kerry ^f  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c Fresenius Medical Care   (Russian Federation)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Columbia Nephrology Associates ^*  (United States)

^f AMGEN INC   (United States)

Author keywords

Clinical nephrology; Dialysis; ESRD; Hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D DERIVATIVE; BIOLOGICAL MARKER; CALCIMIMETIC AGENT; FIBROBLAST GROWTH FACTOR; PTH PROTEIN, HUMAN; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CANADA; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RISK FACTOR; RUSSIAN FEDERATION; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; AUSTRALIA; BIOMARKERS; CALCIMIMETIC AGENTS; CALCIUM; CANADA; CHI-SQUARE DISTRIBUTION; CINACALCET HYDROCHLORIDE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; RUSSIA; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN D;

EID: 84930429203     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03270314     Document Type: Article

References (36)

1. GutiérrezOM, MannstadtM, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
2. Kendrick J, Cheung AK, Kaufman JS,Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
3. Silver J, Naveh-Many T: FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 9: 641-649, 2013
4. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, Rodriguez M: FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21: 1125-1135, 2010
5. Zisman AL,Wolf M: Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 19: 335-342, 2010
6. Burnett-Bowie SM, Henao MP,Dere ME, LeeH, Leder BZ: Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25- dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 24: 1681-1685, 2009
7. Lavi-Moshayoff V,Wasserman G, Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high- FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
8. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, de Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E: Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 80: 475-482, 2011
9. Rhee Y, BiviN, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T: Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49: 636-643, 2011
10. Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB: The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: A potential role for PTH(7-84). J Clin EndocrinolMetab 95: 2772-2780, 2010
11. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J,Go AS, Rosas SE,Nessel L, Townsend RR, Feldman HI, St John SuttonM,Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
12. Helvig CF, CuerrierD,Hosfield CM, Ireland B, Kharebov AZ, Kim JW, Ramjit NJ, Ryder K, Tabash SP, Herzenberg AM, Epps TM, Petkovich M:Dysregulation of renal vitaminDmetabolismin the uremic rat. Kidney Int 78: 463-472, 2010
13. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
14. Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D: Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad SciUS A 101: 5140-5145, 2004
15. Yamaguchi T: The calcium-sensing receptor in bone. J Bone Miner Metab 26: 301-311, 2008
16. Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S: Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: Results of the IMPACT- SHPT study. Nephrol Dial Transplant 29: 899-905, 2014
17. Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L: Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 27: 2263-2269, 2012
18. Hryszko T, Brzosko S, Rydzewska-Rosolowska A, Koc-Zorawska E, Mysliwiec M: Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol 44: 1479-1486, 2012
19. Kim HJ, Kim H, Shin N, Na KY, Kim YL, Kim D, Chang JH, Song YR, Hwang YH, Kim YS, Ahn C, Lee J, Oh KH; Representing the Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect Of iPTH Level (CUPID) Study Group: Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: A randomized controlled study. BMC Nephrol 14: 112, 2013
20. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M: Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27: 784-790, 2012
21. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79: 112-119, 2011
22. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5: 110-116, 2010
23. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M: Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44: 481-487, 2004
24. Takahashi H, Komaba H, Takahashi Y, Sawada K, Tatsumi R, Kanai G, Suzuki H, Kakuta T, Fukagawa M: Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 99: E652-E658, 2014
25. Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S: Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study. Nephrol Dial Transplant 27: 3270-3278, 2012
26. Quinn SJ, Thomsen AR, Pang JL, Kantham L, Bräuner-Osborne H, Pollak M,GoltzmanD, Brown EM: Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 304: E310-E320, 2013
27. Moe SM: Cinacalcet decreases FGF23 levels in prevalent dialysis patients compared to placebo. Presented at the American Society of Nephrology Kidney Week 2013, Atlanta, GA, November 5-10, 2013
28. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E: Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 298: F1315-F1322, 2010
29. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J AmSoc Nephrol 23: 1407-1415, 2012
30. Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM: Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 117: c74-c82, 2011
31. Ketteler M, Petermann AT: Phosphate and FGF23 in early CKD: On how to tackle an invisible foe. Nephrol Dial Transplant 26: 2430-2432, 2011
32. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
33. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 59: 177-185, 2012
34. Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, Aljama P: The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 80: 17-22, 2013
35. David V, Dai B, Martin A, Huang J, Han X, Quarles LD: Calcium regulates FGF-23 expression in bone. Endocrinology 154: 4469- 4482, 2013
36. Messa P, Macário F, YaqoobM, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36-45, 2008